Epithelial-derived IL-33 promotes intestinal tumorigenesis in ApcMin/+ mice
Increased expression of Interleukin (IL)-33 has been detected in intestinal samples of patients with ulcerative colitis, a condition associated with increased risk for colon cancer, but its role in the development of colorectal cancer has yet to be fully examined. Here, we investigated the role of e...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2017-07, Vol.7 (1) |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Increased expression of Interleukin (IL)-33 has been detected in intestinal samples of patients with ulcerative colitis, a condition associated with increased risk for colon cancer, but its role in the development of colorectal cancer has yet to be fully examined. Here, we investigated the role of epithelial expressed IL-33 during development of intestinal tumors. IL-33 expression was detected in epithelial cells in colorectal cancer specimens and in the
Apc
Min/
+
mice. To better understand the role of epithelial-derived IL-33 in the intestinal tumorigenesis, we generated transgenic mice expressing IL-33 in intestinal epithelial cells (
V33
mice).
V33 Apc
Min/
+
mice, resulting from the cross of
V33
with
Apc
Min/
+
mice, had increased intestinal tumor burden compared with littermate
Apc
Min/
+
mice. Consistently,
Apc
Min/
+
mice deficient for IL-33 receptor (ST2), had reduced polyp burden. Mechanistically, overexpression of IL-33 promoted expansion of ST2
+
regulatory T cells, increased Th2 cytokine milieu, and induced alternatively activated macrophages in the gut. IL-33 promoted marked changes in the expression of antimicrobial peptides, and antibiotic treatment of
V33 Apc
Min/
+
mice abrogated the tumor promoting-effects of IL-33 in the colon. In conclusion, elevated IL-33 signaling increases tumor development in the
Apc
Min/
+
mice. |
---|---|
ISSN: | 2045-2322 |
DOI: | 10.1038/s41598-017-05716-z |